Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTR versus Copaxone and placebo in relapsing-remitting multiple sclerosis
2011-000888-27Phase 3Completed
- Sponsor
- Synthon
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Synthon. Primary endpoint: Mean number of gadolinium-enhancing lesions. Started Jun 2011; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2011-000888-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000888-27.